SH-4, a representative metastatic melanoma model, was engineered to generate SH-4 PD-L1 OE and SH-4 PD-L1 KO (PD-L1-deficient) cell lines (Figure S3) for use as target cells to investigate the therapeutic effectiveness of MC9999 CAR T cells against melanoma. This evidence concerns the gene CD274 and melanoma.